1420477-60-6 acalabrutinib

Cov Khoom Siv

Cov tsos daj
Melting point:>133 Qib (Dec.)
Qeeb 1.37 ± 0. 1 g / cm3
Cia temp. Lub tub yees
solubility soluble hauv dmo (txog li tsawg kawg 25 mg / ml)
PKA11.47 ± 0. 70

 

Daim Ntawv Thov:

Acalabrutinib, ib ob-tiam btk inhiboritor, yog ib tug irreversible btk inibritic feem ntau siv rau kev kho mob ntawm mantle cell lymphoma. Nyob rau hauv Lub Ob Hlis 2016, Astraeteca tau txais 55% Ceg hauv aitafharma rau $ 4 billion (thaum tseem muaj cov seem 45%), yog li nqa acalabrutinib hauv nws lub kaus. Nyob rau lub Kaum Hlis 2017, tom qab tau pom zoo kev pom zoo thiab nrawm, Acalabrutinib tau pom zoo los ntawm kev siv hauv Mantle Cell Lymphoma cov neeg mob uas tau txais lwm txoj kev kho mob. Hauv 2019, raws li theem III cov kev sim siab tau pom zoo rau kev kho mob ntawm cov neeg laus ntawm cov neeg laus uas muaj cov neeg laus hauv CLL lossis Cell).

 

Cov lus txhais lus:

Acalabrutinib

1420477-60-6

Acp -196

Calquence

Acalabrutinib (acp -196)

Acalabrutinib

Acalabrutinibum

{{0 {0}} [{{{1} {{{{{{{{} ynoylprolidin {}}}}}}} L] Imidazo [1, 5- a] pyazin {9}} {-pyridin {} {}} ylbenlenhleninamide

(S) -4- (8-}}}}}} {} -2- yl ) Imidazo [1, {5- a] pyazin {{{8} {{{} {yl) benzamide

Benzamide, {{0 {0}} ({1}} {}}} {} {} {{{8} p yrrolidinyl) iMidazo (1, {10}} A) pyazin {{{{} {{} pyridineyl-

Calquence

(S) -4- (8- {} {} {} {} {5}} yl) imidazo [1, {5- a] pyazin -1- yl) -n- (pyridin {} {yl) benzamide

{{0 {0}} [{{{1} {{{{{{{{} ynoylprolidin {}}}}}}} L] Imidazo [1, {8}} a] pyazin {9}} {}} pyridyl) benzamide

(S) -4- (8-}}}}}} {} -2- yl ) iMidazo (1, 5- A) pyrazin -1- yl) -n- (pyridin {} {yl) benzamide

{{0 {0}} ({{1} {{} {} {4} {} {} {} {}}} y l) imidazo (1, {8}} A) pyrazin {9} {} {{12} {} {yl) benzamide

{{0 {0}} [8- {} {} {} {} {{8} pyrro lidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide; ACP 196

Acalabrutinib (tus qauv)

Acp -196; acalabrutinib

 

 

 

Cim npe nrov: 1420477-60-6 acalabrutinib, Tuam Tshoj 1420477-60-6 acalabrutinib manufacturers, lwm tus neeg